Showing 131-140 of 9958 results for "".
Quarantine Quorum: Circling the Wagons
https://practicaldermatology.com/topics/practice-management/quarantine-quorum-circling-the-wagons/18180/With Quarantine Quorum, host Neal Bahtia, MD provides a diary of life during the COVID-19 pandemic, talking to members of the dermatology community as they adapt to ongoing changes in their personal and private lives. In this edition, Hilary Baldwin, MD; Adam J. Friedman, MD; Mark Kaufmann, MD; andConnecting and Networking at DERM2021
https://practicaldermatology.com/series/dermatology-education-foundation/connecting-and-networking-at-derm2021/19995/Kara S. Gooding, MMS, PA-C says being able to connect with colleagues in sessions and at social events were an invaluable part of the DERM2021 NP/PA CME Conference.If you weren't a doctor what would you have been?
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/if-you-werent-a-doctor-what-would-you-have-been/19999/Ronda S. Farah, MD talks about her early dream of being a figure skater, how her interests transitioned to medicine, and why she's currently interested in the hair cosmetics industry.The Shape of the Contouring Market: Expert Tips on Energy-based Body Treatments
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-shape-of-the-contouring-market-expert-tips-on-energy-based-body-treatments/20332/Experienced clinicians weigh in on their approach to identifying, educating, and treating patients for body contouring.Dupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects sComorbidities in Immune-mediated Skin Disorders: What’s Coming
https://practicaldermatology.com/issues/january-february-2025/comorbidities-in-immune-mediated-skin-disorders-whats-coming/32968/Comorbidities in immune-mediated skin disorders (IMSDs) occur frequently and have a significant impact on disease severity, treatment, prognosis, and quality of life.What to do if your practice’s social accounts are inactive
https://practicaldermatology.com/topics/practice-management/what-to-do-if-your-practices-social-accounts-are-inactive/20127/Social media is the can’t miss marketing platform of 2022. However, it has been around long enough that many businesses have already tried it and given up years ago. If you are among the many dermatology practices with an old, outdated, nearly inactive Facebook or other social accounts, check out thSkin Reactions: Understanding New Drug Adverse Effects
https://practicaldermatology.com/conferences/aad-summer-2021/skin-reactions-understanding-new-drug-adverse-effects/19975/In addition to needing to stay abreast of new drugs in dermatology, it's important for dermatologists to stay informed about new medications that come to market in general. Vinod Nambudiri, MD, MBA says there are often dermatology-related adverse events that need to be managed. He discusses new cancThree Digital Marketing Predictions for Dermatology Marketers in 2019
https://practicaldermatology.com/topics/practice-management/predictions/18377/The trends in digital marketing are likely to have a significant impact on dermatology marketers in 2019. This Ekwa Marketing video looks at the top three predictions for the sector.New eRelevance Services, Cosmetic Bootcamp Updates, Leo & AID Partnership
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-new-erelevance-services-cosmetic-bootcamp-updates-leo-aid-partnership/18291/eRelevance has launched a suite of 4 services intended to support aesthetic practices in optimizing their marketing strategies to capture, convert, and retain patients. CEO Bob Fabbio discusses. Aesthetic education takes center stage at Cosmetic Boot Camp in Aspen. The meeting is open only to board